TOP PAGE
ENGLISH
JAPANESE
|
CONNECT WITH US:
Home
About
Services
Contact
Log in
*
Home
Press release
Mar 05, 2021 17:51 JST
Source:
Eisai
Eisai to Present Latest Data on Pipeline Assets in the Area of Alzheimer's Disease and Dementia at the 15th International Conference on Alzheimer's and Parkinson's Disease
TOKYO, Mar 05, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced today that the latest data from its Alzheimer's disease (AD) and dementia pipeline, including the investigational anti-amyloid beta (Aß) protofibril antibody lecanemab (Development Code: BAN2401), will be presented at the 15th International Conference on Alzheimer's and Parkinson's Disease (AD/PD2021) to be held virtually from March 9 to 14, 2021.
Regarding lecanemab, preliminary analysis results of changes in brain-Aß amounts as observed in subjects of the ongoing open-label extension (OLE) of the Phase II study (Study 201) will be presented orally.
Regarding aducanumab, for which applications are currently underway in the U.S., Europe and Japan, Biogen Inc. will conduct presentations on the correlation of amyloid PET and cerebrospinal fluid (CSF) biomarkers in the Phase III studies (EMERGE/ENGAGE), as well as evaluations of the safety and efficacy of aducanumab in early AD. Lecanemab and aducanumab are being jointly developed by Eisai and Biogen.
Additionally, regarding the joint research effort with Sysmex Corporation for creation of simplified diagnosis of Alzheimer's disease (AD) using blood, a presentation is planned on new data regarding prediction of amyloid positivity through plasma Aß ratio measurement on a fully automated immunoassay incorporating APOE4 status, HISCLTM*.
In addition to presenting the latest data, Eisai and Biogen are planning to host a symposium focusing on the role of Aß in the AD pathology, entitled "The Science Behind the Aß Pathway in AD". Dr. Jeffrey Cummings, Dr. John Hardy, Dr. Colin Masters, and Dr. Philip Schelten, four renowned faculty in this field, will provide a discussion about the loss of Aß homeostasis as an early pathophysiological event within the AD continuum, along with a state-of-the-art presentation on the in vivo biomarkers of Aß.
Eisai aims to realize the prevention and cure of dementia through a multi-dimensional and holistic approach with a foundation of over 35 years of experience of drug discovery activities in the area of AD and dementia. Eisai strives to create innovative medicines as soon as possible to further contribute to addressing the unmet medical needs of, as well as increasing the benefits provided to, those living with the disease and their families.
*HISCLTM is a trademark of Sysmex Corporation.
Source: Eisai
Sectors: BioTech
Copyright ©2026 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
Related Press Release
Pfizer and Eisai Commence Co-promotion of "NURTEC(R)" for the Acute Treatment and Prophylaxis (Preventive Treatment) of Migraine
July 27 2026 22:50 JST
Marketing Authorization Application for In-house Developed Insomnia Drug Lemborexant Accepted for Evaluation by European Medicines Agency (EMA)
July 17 2026 23:24 JST
LEQEMBI(R) Real-World LEADER Study Presented at AAIC(R) 2026 Finds Over 75% of Early Alzheimer's Patients Enrolled in the Study Remained Stable and Nearly 7% Improved Over an Average of 17 Months of Treatment
July 15 2026 23:18 JST
FDA Approves LEQEMBI IQLIK(R) (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer's Disease
July 15 2026 22:51 JST
Eisai Presents Latest Findings Showed Etalanetug Reduced Alzheimer's Disease Tau Tangle-Specific Plasma Biomarker MTBR-tau243 at Alzheimer's Association International Conference(R) (AAIC(R)) 2026
July 15 2026 22:21 JST
LEQEMBI(R) Subcutaneous Autoinjector Clinical Data Supports Similar Efficacy and Safety to IV Formulation in Early Alzheimer's Disease Presented at the Alzheimer's Association International Conference(R) (AAIC(R)) 2026
July 13 2026 23:06 JST
Eisai to Showcase Alzheimer's Disease Portfolio with More Than 50 Presentations at the Alzheimer's Association International Conference(R) 2026 (AAIC(R))
July 02 2026 21:45 JST
UCL and Eisai renew partnership to accelerate treatments for neurodegenerative diseases
July 02 2026 21:01 JST
Eisai Announces Strategic Investment Supported by the UK Government's LSIMF
June 17 2026 12:28 JST
Eisai Deepens Body of Clinical Evidence for LENVIMA(R) (Lenvatinib) Across Established Indications at ASCO 2026
May 21 2026 23:23 JST
More Press release >>
Latest Press Release
ispace and Mitsubishi Heavy Industries Agree to Launch Mission 3 ULTRA Lunar Lander Aboard H3 Rocket
Jul 29, 2026 21:08 JST
Mazda Begins Local Assembly of MAZDA CX-30 in Indonesia
Jul 29, 2026 20:53 JST
Fujitsu initiates development of proprietary AI platform for financial institutions
Jul 28, 2026 19:53 JST
Toyota, Volvo Group and Daimler Truck AG sign binding agreement for Toyota to join cellcentric as equal shareholder
Jul 28, 2026 00:39 JST
Pfizer and Eisai Commence Co-promotion of "NURTEC(R)" for the Acute Treatment and Prophylaxis (Preventive Treatment) of Migraine
Jul 27, 2026 23:50 JST
Launch of a proof-of-concept experiment for a next-generation distributed AI processing infrastructure aiming to realize the Watt-Bit vision
Jul 27, 2026 23:24 JST
Next-generation spectator experience at KYOJO CUP: AI selects and delivers "The moment you want to see" with ultra-low latency
Jul 27, 2026 22:40 JST
Sharp Acquires Vietnamese Corporation Engaged in Solar EPC And O&M Business as A Wholly Owned Subsidiary
Jul 27, 2026 22:02 JST
Collaboration Agreement announced by Sovereign Effects Partners to support GCAP
Jul 27, 2026 21:49 JST
Chunghwa Telecom, Fujitsu and 1Finity to accelerate All-Photonics Network deployment and advance quantum technologies in Taiwan through strategic partnership
Jul 27, 2026 21:08 JST
JCB and Fiuu Collaborate to Expand JCB Acceptance Across Southeast Asia
Jul 23, 2026 12:00 JST
Marketing Authorization Application for In-house Developed Insomnia Drug Lemborexant Accepted for Evaluation by European Medicines Agency (EMA)
Jul 18, 2026 00:24 JST
Hitachi and NVIDIA collaborate to advance HMAX and enable end-to-end autonomous operations through the integrated control of physical AI
Jul 17, 2026 23:35 JST
Toyota's First "BE creation" Spin-Off Begins Operations in Japan
Jul 17, 2026 23:00 JST
MHI Advances AI Infrastructure Commercialization with U.S. Deployment of 10MW-Class Chiller and MCP Development
Jul 17, 2026 22:47 JST
Noetra Launches Full-Scale R&D for Japan-Developed Multimodal Foundation Model
Jul 17, 2026 22:16 JST
Mitsubishi Motors Launches the Xforce HEV in Indonesia
Jul 17, 2026 21:47 JST
Fujitsu to explore physical AI development and implementation across industries with FANUC, Yaskawa Electric, and Kawasaki Heavy Industries integrating NVIDIA technology
Jul 17, 2026 21:05 JST
JCB Celebrates 30 Years of Trust, Honoring 70 Years of Japan-Philippines Friendship
Jul 17, 2026 10:00 JST
TANAKA Commences Operation of "TANAKA H2 Nexus", One of Japan's Largest 500 kW Pure Hydrogen Fuel Cell Power Generation Facilities
Jul 16, 2026 22:00 JST
More Latest Release >>